Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17063892 | 1.00 | HSD17B10 (0.46) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2893906 | 1.00 | HSD17B10 (0.46) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL14368609 | 1.00 | HSD17B10 (0.46) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2893902 | 1.00 | HSD17B10 (0.46) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2893904 | 1.00 | HSD17B10 (0.46) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL8228626 | 1.00 | HSD17B10 (0.46) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL8220765 | 0.95 | HSD17B10 (0.42) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL8228189 | 0.95 | HSD17B10 (0.42) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2897865 | 0.95 | HSD17B10 (0.42) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2894345 | 0.95 | HSD17B10 (0.42) | HSD17B10LMNANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2032568-A2 | POLYCYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF THE METABOTROPIC GLUTAMATE 5 RECEPTOR | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007130823-A2 | POLYCYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF THE METABOTROPIC GLUTAMATE 5 RECEPTOR | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259923-A1 | MGluR5 modulators IV | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | HSD17B10 2837/4885LMNA 1258/4885NPSR1 4794/4885 |
| US-20070259923-A1 | MGluR5 modulators IV | GRM5, GRM4, GRIK5 | HSD17B10 2691/4885LMNA 4640/4885NPSR1 252/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | HSD17B10 778/4885LMNA 3489/4885NPSR1 38/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | HSD17B10 2837/4885LMNA 1258/4885NPSR1 4794/4885 |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | HSD17B10 2837/4885LMNA 1258/4885NPSR1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.